Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 Jul;45(1):248–254. doi: 10.1128/iai.45.1.248-254.1984

Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis.

G R Siber, D M Ambrosino, J McIver, T J Ervin, G Schiffman, S Sallan, G F Grady
PMCID: PMC263308  PMID: 6429048

Abstract

As a first step in exploring the feasibility of passive antibody prophylaxis and therapy of serious infections caused by common encapsulated bacteria, we have immunized healthy adults with Haemophilus influenzae type b vaccine, 14-valent pneumococcal vaccine, and meningococcal group A and C vaccine; collected plasma by repeated pheresis; and purified a hyperimmune globulin termed bacterial polysaccharide immune globulin by the cold-ethanol fractionation method of Cohn and Oncley. Specific antibacterial antibody concentrations were measured in individual donors before and after immunization. In addition, antibody concentrations were measured in plasma pools prepared from immunized donors and from unimmunized controls and in the immunoglobulin-containing Cohn-Oncley fractions II and III derived from the respective plasma pools. A comparison of Cohn-Oncley fractions II, which contain primarily immunoglobulin G and which are used therapeutically as immune globulin, revealed that antibody to H. influenzae type b was enriched 15.3-fold and that antibody to meningococcal serogroups and pneumococcal types was enriched a mean of 4.4-fold (range, 1.2- to 9.9-fold). Enrichment of antibacterial antibody in Cohn fraction III, which contains substantial amounts of immunoglobulin M and immunoglobulin A in addition to immunoglobulin G, closely paralleled that in fraction II. Only antibodies to pneumococcal types 1 and 7 were increased disproportionately in fraction III. Based on the clinical experience that conventional immune serum globulin at a dose of 100 mg/kg protects agammaglobulinemic patients for ca. 1 month, we estimate that bacterial polysaccharide immune globulin, in similar dosage, will provide protection from systemic H. influenzae type b infection for 4 to 6 months and from pneumococcal and meningococcal infections for 3 to 4 months.

Full text

PDF
248

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AUSTRIAN R., GOLD J. PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. Ann Intern Med. 1964 May;60:759–776. doi: 10.7326/0003-4819-60-5-759. [DOI] [PubMed] [Google Scholar]
  2. Alper C. A. Plasma protein measurements as a diagnostic aid. N Engl J Med. 1974 Aug 8;291(6):287–290. doi: 10.1056/NEJM197408082910606. [DOI] [PubMed] [Google Scholar]
  3. Ambrosino D., Schreiber J. R., Daum R. S., Siber G. R. Efficacy of human hyperimmune globulin in prevention of Haemophilus influenzae type b disease in infant rats. Infect Immun. 1983 Feb;39(2):709–714. doi: 10.1128/iai.39.2.709-714.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun. 1983 Jan;39(1):233–238. doi: 10.1128/iai.39.1.233-238.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Anderson P., Johnston R. B., Jr, Smith D. H. Human serum activities against Hemophilus influenzae, type b. J Clin Invest. 1972 Jan;51(1):31–38. doi: 10.1172/JCI106793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
  7. Blaese R. M., Strober W., Brown R. S., Waldmann T. A. The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet. 1968 May 18;1(7551):1056–1061. doi: 10.1016/s0140-6736(68)91411-6. [DOI] [PubMed] [Google Scholar]
  8. Chu C., Schneerson R., Robbins J. B., Rastogi S. C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun. 1983 Apr;40(1):245–256. doi: 10.1128/iai.40.1.245-256.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Coulehan J. L., Michaels R. H., Williams K. E., Lemley D. K., North C. Q., Jr, Welty T. K., Rogers K. D. Bacterial meningitis in Navojo Indians. Public Health Rep. 1976 Sep-Oct;91(5):464–468. [PMC free article] [PubMed] [Google Scholar]
  10. Daum R. S., Glode M. P. Rifampin prophylaxis against H. flu type b spread - is it valid? Hosp Pract (Off Ed) 1982 Nov;17(11):124A-C, 124K-L, 124N-P. [PubMed] [Google Scholar]
  11. Deal W. B., Sanders E. Efficacy of rifampin in treatment of meningococcal carriers. N Engl J Med. 1969 Sep 18;281(12):641–645. doi: 10.1056/NEJM196909182811203. [DOI] [PubMed] [Google Scholar]
  12. Devine L. F., Hannah J. M., Hagerman C. R., Rhode S. L., 3rd, Peckinpaugh R. O. Minocycline and rifampin: proposed treatment regimen for the elimination of meningococci from the nasopharynges of healthy carriers. Mil Med. 1973 Jan;138(1):20–24. [PubMed] [Google Scholar]
  13. Eraklis A. J., Kevy S. V., Diamond L. K., Gross R. E. Hazard of overwhelming infection after splenectomy in childhood. N Engl J Med. 1967 Jun 1;276(22):1225–1229. doi: 10.1056/NEJM196706012762203. [DOI] [PubMed] [Google Scholar]
  14. Farries J. S., Dickson W., Greenwood E., Malhotra T. R., Abbott J. D., Jones D. M. Meningococcal infections in Bolton, 1971-74. Lancet. 1975 Jul 19;2(7925):118–120. doi: 10.1016/s0140-6736(75)90016-1. [DOI] [PubMed] [Google Scholar]
  15. Favorova L. A., Sokova I. N., Chernyshova T. F., Khrometskaia T. M., Teleshevskaia E. A. Itogi kontroliruemogo épidemiologicheskogo opyta po primeneniiu platsentarnogo gamma-globulina v ochagakh meningokokkovoi infektsii. Zh Mikrobiol Epidemiol Immunobiol. 1975 Jun;(6):15–18. [PubMed] [Google Scholar]
  16. Fraser D. W., Geil C. C., Feldman R. A. Bacterial meningitis in Bernalillo County, New Mexico: a comparison with three other American populations. Am J Epidemiol. 1974 Jul;100(1):29–34. doi: 10.1093/oxfordjournals.aje.a112005. [DOI] [PubMed] [Google Scholar]
  17. Gold R., Lepow M. L., Goldschneider I., Draper T. L., Gotschlich E. C. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest. 1975 Dec;56(6):1536–1547. doi: 10.1172/JCI108235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gordon J. M., Cohen P., Finlayson J. S. Levels of anti-A and anti-B in commercial immune globulins. Transfusion. 1980 Jan-Feb;20(1):90–92. doi: 10.1046/j.1537-2995.1980.20180125049.x. [DOI] [PubMed] [Google Scholar]
  19. Gotschlich E. C., Goldschneider I., Artenstein M. S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969 Jun 1;129(6):1367–1384. doi: 10.1084/jem.129.6.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gotschlich E. C., Rey M., Triau R., Sparks K. J. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest. 1972 Jan;51(1):89–96. doi: 10.1172/JCI106801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hill J. C. From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on Haemophilus influenzae type B vaccines. J Infect Dis. 1983 Jul;148(1):167–175. doi: 10.1093/infdis/148.1.167. [DOI] [PubMed] [Google Scholar]
  22. Hilleman M. R., Carlson A. J., Jr, McLean A. A., Vella P. P., Weibel R. E., Woodhour A. F. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis. 1981 Mar-Apr;3 (Suppl):S31–S42. doi: 10.1093/clinids/3.supplement_1.s31. [DOI] [PubMed] [Google Scholar]
  23. Levine L., McComb J. A., Dwyer R. C., Latham W. C. Active-passive tetanus immunization. Choice of toxoid, dose of tetanus immune globulin and timing of injections. N Engl J Med. 1966 Jan 27;274(4):186–190. doi: 10.1056/NEJM196601272740404. [DOI] [PubMed] [Google Scholar]
  24. Marrie T. J., Schiffman G., Bortolussi R., Field C., Whalen A. Humoral immune response of kidney transplant recipients to pneumococcal vaccine. Proc Soc Exp Biol Med. 1981 May;167(1):62–69. doi: 10.3181/00379727-167-41126. [DOI] [PubMed] [Google Scholar]
  25. Murphy T. V., McCracken G. H., Jr, Zweighaft T. C., Hansen E. J. Emergence of rifampin-resistant Haemophilus influenzae after prophylaxis. J Pediatr. 1981 Sep;99(3):406–409. doi: 10.1016/s0022-3476(81)80328-9. [DOI] [PubMed] [Google Scholar]
  26. O'Reilly R. J., Anderson P., Ingram D. L., Peter G., Smith D. H. Circulating polyribophosphate in Hemophilus influenzae, type b meningitis. Correlation with clinical course and antibody response. J Clin Invest. 1975 Oct;56(4):1012–1022. doi: 10.1172/JCI108148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Overturf G. D., Powars D., Baraff L. J. Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child. 1977 Jul;131(7):784–787. doi: 10.1001/archpedi.1977.02120200066014. [DOI] [PubMed] [Google Scholar]
  28. Oxelius V. A., Laurell A. B., Lindquist B., Golebiowska H., Axelsson U., Björkander J., Hanson L. A. IgG subclasses in selective IgA deficiency: importance of IgG2-IgA deficiency. N Engl J Med. 1981 Jun 11;304(24):1476–1477. doi: 10.1056/NEJM198106113042408. [DOI] [PubMed] [Google Scholar]
  29. Peltola H., Mäkelä H., Käyhty H., Jousimies H., Herva E., Hällström K., Sivonen A., Renkonen O. V., Pettay O., Karanko V. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977 Sep 29;297(13):686–691. doi: 10.1056/NEJM197709292971302. [DOI] [PubMed] [Google Scholar]
  30. Powars D., Overturf G., Weiss J., Lee S., Chan L. Pneumococcal septicemia in children with sickle cell anemia. Changing trend of survival. JAMA. 1981 May 8;245(18):1839–1842. [PubMed] [Google Scholar]
  31. Robbins J. B., Parke J. C., Jr, Schneerson R., Whisnant J. K. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res. 1973 Mar;7(3):103–110. doi: 10.1203/00006450-197303000-00001. [DOI] [PubMed] [Google Scholar]
  32. Schmid G. P., Smith R. P., Baltch A. L., Hall C. A., Schiffman G. Antibody response to pneumococcal vaccine in patients with multiple myeloma. J Infect Dis. 1981 Apr;143(4):590–597. doi: 10.1093/infdis/143.4.590. [DOI] [PubMed] [Google Scholar]
  33. Schneerson R., Rodrigues L. P., Parke J. C., Jr, Robbins J. B. Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b. J Immunol. 1971 Oct;107(4):1081–1089. [PubMed] [Google Scholar]
  34. Schur P. H., Rosen F., Norman M. E. Immunoglobulin subclasses in normal children. Pediatr Res. 1979 Mar;13(3):181–183. doi: 10.1203/00006450-197903000-00010. [DOI] [PubMed] [Google Scholar]
  35. Siber G. R., Ambrosino D. M., Gorgone B. C. Blood-group-A-like substance in a preparation of pneumococcal vaccine. Ann Intern Med. 1982 May;96(5):580–586. doi: 10.7326/0003-4819-96-5-580. [DOI] [PubMed] [Google Scholar]
  36. Siber G. R. Bacteremias due to Haemophilus influenzae and Streptococcus pneumoniae: their occurrence and course in children with cancer. Am J Dis Child. 1980 Jul;134(7):668–672. doi: 10.1001/archpedi.1980.02130190036009. [DOI] [PubMed] [Google Scholar]
  37. Siber G. R., Ransil B. J. Methods for the analysis of antibody responses to vaccines or other immune stimuli. Methods Enzymol. 1983;93:60–78. doi: 10.1016/s0076-6879(83)93034-3. [DOI] [PubMed] [Google Scholar]
  38. Siber G. R., Weitzman S. A., Aisenberg A. C., Weinstein H. J., Schiffman G. Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. N Engl J Med. 1978 Aug 31;299(9):442–448. doi: 10.1056/NEJM197808312990903. [DOI] [PubMed] [Google Scholar]
  39. Smith D. H., Peter G., Ingram D. L., Harding A. L., Anderson P. Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics. 1973 Nov;52(5):637–644. [PubMed] [Google Scholar]
  40. Smith G. N., Griffiths B., Mollison D., Mollison P. L. Uptake of IgG after intramuscular and subcutaneous injection. Lancet. 1972 Jun 3;1(7762):1208–1212. doi: 10.1016/s0140-6736(72)90926-9. [DOI] [PubMed] [Google Scholar]
  41. Ward J. I., Fraser D. W., Baraff L. J., Plikaytis B. D. Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med. 1979 Jul 19;301(3):122–126. doi: 10.1056/NEJM197907193010302. [DOI] [PubMed] [Google Scholar]
  42. Ward J. I., Margolis H. S., Lum M. K., Fraser D. W., Bender T. R., Anderson P. Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet. 1981 Jun 13;1(8233):1281–1285. doi: 10.1016/s0140-6736(81)92458-2. [DOI] [PubMed] [Google Scholar]
  43. Winston D. J., Schiffman G., Wang D. C., Feig S. A., Lin C. H., Marso E. L., Ho W. G., Young L. S., Gale R. P. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med. 1979 Dec;91(6):835–841. doi: 10.7326/0003-4819-91-6-835. [DOI] [PubMed] [Google Scholar]
  44. Yount W. J., Dorner M. M., Kunkel H. G., Kabat E. A. Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers. J Exp Med. 1968 Mar 1;127(3):633–646. doi: 10.1084/jem.127.3.633. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES